Arq. Bras. Oftalmol. 2023; 86 (5): 10.5935/0004-2749.20230046
Total: 2639
Cinthya Parra-Bernal1; Jorge A Aguilera-Partida2; Lauren A Dalvin3; Abelardo A Rodríguez-Reyes4; David Ancona-Lezama1
DOI: 10.5935/0004-2749.20230046
1. Ocular Oncology Service, Institute of Ophthalmology and Visual Sciences, Tecnologico de Monterrey, Monterrey, Mexico
2. Uveitis and Ocular Inflammation Service, Clínica Oftalmológica Santa Lucía, Guadalajara, Jalisco, Mexico
3. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
4. Ophthalmic Pathology Service, Asociación Para Evitar La Ceguera en México, Hospital Dr. Luis Sanchez Bulnes, Mexico City, Mexico.
David Ancona-Lezama
E-mail: [email protected]
Funding: This study received no specific financial support.
Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose.
Informed consent was obtained from all patients included in this study.
How to cite this article:
ABO is licensed under a Creative Commons Attribution-NonComercial 4.0 Internacional.
